Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of TDF/FTC with raltegravir, dolutegravir, or elvitegravir/cobicistat on renal tubular function in antiretroviral-naive HIV-1 patients
2014-004578-40Phase 4Completed
- Sponsor
- St Stephen's AIDS Trust
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + tenofovir disoproxil, raltegravir, dolutegravir and emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (3 arms), sponsored by St Stephen's AIDS Trust. Primary endpoint: Change in retinol-binding protein/creatinine ratio at 24 weeks. Started Jan 2016; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxilraltegravirdolutegraviremtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-004578-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004578-40.